US5266489A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Recombinant herpesviruses, in particular for the production of vaccines, process for preparing them, plasmids produced during this process and vaccines obtained
Assignee: Boehringer Ingelheim Animal Health France SAS
•
Filing: 1991-03-07
•
Granted: 1993-11-30
•
Expires: 2011-03-07
Abstract
Abstract PCT No. PCT/FR91/00184 Sec. 371 Date Jan. 3, 1992 Sec. 102(e) Date Jan. 3, 1992 PCT Filed Mar. 7, 1991 PCT Pub. No. WO91/13995 PCT Pub. Date Sep. 19, 1991.The recombinant virus chosen from the turkey herpesvirus(HVT), Aujeszky's disease virus (PRV), infectious bovine rhinotracheitis virus (BHV) feline infectious rhinotracheitis virus (FHV), equine rhinopneumonia virus (EHV), canine herpesvirus (CHV), duck herpesvirus, human simplex herpesvirus (HSV), varicella virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), comprises at least one heterologous gene, coding particularily for a viral, bacterial or parasitic immunogen inserted in the region of the genome of the said virus corresponding to the gene of the small sub-unit RR2 of ribonucleotide reductase so that it may be expressed. The method for preparing a virus of this type involves inserting the heterlogous gene into the said region of the genome, particularly after partial or total deletion of this region. The recombiant virus obtained may be used particularly for preparing living vaccines. The small sub-unit of the ribonucleotide reductase of the turkey herpesvirus (HVT) has been sequenced.
Inventors
- 👤 Arielle Rey-Senelonge
- 👤 Gilla Kohen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 08:44
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; A; A61; A61P; A61P31/00; A61P31/04; A61P31/12; A61P31/20; A61P31/22; C07; C07K; C07K14/00; C07K14/005; A61K; A61K39/00; C12N2710/00; C12N2710/00011; C12N2710/16011; C12N2710/16711; C12N2710/16722; C12N2710/16741; C12N2710/16743; C12N2760/00; C12N2760/00011; C12N2760/18011; C12N2760/18111; C12N2760/18122
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
38 words
Recombinant HVT comprising at least one heterologous gene inserted into the region of the genome of said virus corresponding to the gene for the small subunit RR2 of ribonucleotide reductase, so as to be capable of being expressed.
Claim 2
Dependent Claim
38 words
Recombinant HVT comprising at least one heterologous gene inserted into the region of the genome of said virus corresponding to the gene for the small subunit RR2 of ribonucleotide reductase, so as to be capable of being expressed.
Claim 3
Dependent Claim
20 words
Recombinant virus according to claim 1, characterised in that the heterologous gene codes for a viral, bacterial or parasitic antigen.
Claim 4
Dependent Claim
50 words
Recombinant HVT virus according to claim 2 wherein the antigen is a component of a pathogenic agent of a disease selected from the group consisting of Marek's disease, infectious avian bronchitis, Newcastle disease, fowl plague, Gumboro disease, avian anaemia, egg drop syndrome, fowlpox, infectious laryngotracheitis, coccidiosis, colibacillosis, pasteurellosis and haemophilosis.
Claim 5
Dependent Claim
34 words
Recombinant virus according to claim 2, characterised in that the inserted heterologous gene is capable of being expressed under the control of the transcription regulation sequences of the gene for the small subunit RR2.
Claim 6
Dependent Claim
45 words
Recombinant virus according to claim 2, characterised in that the inserted heterologous gene is capable of being expressed under the control of endogenous promoter sequences from said virus or of exogenous herpesvirus promoter sequences which are transferred to the genome of the virus in question.
Claim 7
Dependent Claim
28 words
Recombinant virus according to claim 2, characterised in that the initiation and termination codons of the RR2 gene are replaced by those of the gene to be inserted.
Claim 8
Dependent Claim
52 words
Process for preparing a recombinant virus from a HVT characterised in that at least one heterologous gene is inserted into the region of the genome of said virus which corresponds to the gene for the small subunit RR2 of ribonucleotide reductase, in such a way that said heterologous gene can be expressed.
Claim 9
Dependent Claim
52 words
Process for preparing a recombinant virus from a HVT characterised in that at least one heterologous gene is inserted into the region of the genome of said virus which corresponds to the gene for the small subunit RR2 of ribonucleotide reductase, in such a way that said heterologous gene can be expressed.
Claim 10
Dependent Claim
82 words
Process according to claim 7, characterized in that a portion of the viral genome sufficient to promote homologous recombination with the HVT genome and containing the gene for the small subunit RR2 is isolated, a partial or total deletion of this gene is carried out and the heterologous gene is inserted into the region corresponding to said gene before inserting the DNA sequence obtained into the genome of the virus by cotransfection into recipient host cells and homologous recombination in said cell.
Claim 11
Dependent Claim
23 words
Process according to claim 7, characterised in that the inserted gene is under the control of transcription regulation sequences of the RR2 gene.
Claim 12
Dependent Claim
36 words
Process according to claim 7, characterised in that the inserted gene is under the control of endogenous HVT promoter sequences or exogenous herpesvirus promoter sequences which are transferred to the genome of the virus in question.
Claim 13
Dependent Claim
27 words
Process according to claim 7 characterised in that the initiation and termination codons of the RR2 gene are replaced by those of the gene to be inserted.
Claim 14
Dependent Claim
188 words
Process for preparing a recombinant HVT, characterised in that: a) a K1 Bam HI fragment of the HVT genome is isolated by digestion of the genome with the restriction enzyme Bam HI, b) this fragment is digested with the restriction enzyme Hind III, to obtain a fragment corresponding to the 5' portion of the RR2 gene and to the region upstream including the promoter, and a fragment corresponding to the 3' portion of the RR2 gene and to the region downstream of this gene, c) the two fragments, 5' and 3', obtained in b) are cloned, respectively, into the vectors pUC18 and pUC19, d) these plasmids are digested, respectively, with the restriction enzyme systems Hind III/Aat II and Xmn I/Aat II and then ligated together to give a new plasmid containing a deletion between the initial Hind III and Xmn I sites, e) restriction sites are created by directed mutagenesis in the plasmid obtained in d), f) a heterologous gene is cloned into these restriction sites, and g) the DNA fragment obtained in f) is inserted into the genome of the HVT virus by cotransfection and homologous recombination.
Claim 15
Dependent Claim
188 words
Process for preparing a recombinant HVT, characterised in that: a) a K1 Bam HI fragment of the HVT genome is isolated by digestion of the genome with the restriction enzyme Bam HI, b) this fragment is digested with the restriction enzyme Hind III, to obtain a fragment corresponding to the 5' portion of the RR2 gene and to the region upstream including the promoter, and a fragment corresponding to the 3' portion of the RR2 gene and to the region downstream of this gene, c) the two fragments, 5' and 3', obtained in b) are cloned, respectively, into the vectors pUC18 and pUC19, d) these plasmids are digested, respectively, with the restriction enzyme systems Hind III/Aat II and Xmn I/Aat II and then ligated together to give a new plasmid containing a deletion between the initial Hind III and Xmn I sites, e) restriction sites are created by directed mutagenesis in the plasmid obtained in d), f) a heterologous gene is cloned into these restriction sites, and g) the DNA fragment obtained in f) is inserted into the genome of the HVT virus by cotransfection and homologous recombination.
Claim 16
Dependent Claim
24 words
Process according to claim 12, characterised in that the heterologous gene codes for an immunogen originating from pathogenic agents associated with an avian disease.
Claim 17
Dependent Claim
7 words
Recombinant virus obtained according to claim 7.
Claim 18
Dependent Claim
9 words
Vaccine comprising a recombinant virus according to claim 1.
Claim 19
Dependent Claim
50 words
Nucleotide sequence designated SEQ ID NO: 1 corresponding to the gene for the small subunit RR2 of ribonucleotide reductase of the HVT or a fragment of said sequence wherein said fragment encodes a polypeptide characterized by the antigenicity of the small subunit RR2 of ribonucleotide reductase of the HVT virus.
Claim 20
Dependent Claim
50 words
Nucleotide sequence designated SEQ ID NO: 1 corresponding to the gene for the small subunit RR2 of ribonucleotide reductase of the HVT or a fragment of said sequence wherein said fragment encodes a polypeptide characterized by the antigenicity of the small subunit RR2 of ribonucleotide reductase of the HVT virus.
Claim 21
Dependent Claim
39 words
Process according to claim 13 wherein the disease is selected from the group consisting of Marek's disease, infectious avian bronchitis, Newcastle disease, fowl plague, Gumboro disease, avian anaemia, egg drop syndrome, fowlpox, infectious laryngotracheitis, coccidiosis, colibacillosis, pasteurellosis and haemophilosis.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-11-29 | 1997-05-31 | 1997-11-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-11-29 | 2001-05-31 | 2001-11-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-11-29 | 2005-05-31 | 2005-11-30 | $7700.00 | Window Closed / Lapsed |